Back to School: How biopharma can reboot drug development. Access exclusive analysis here

J&J intercepts Nextera

How Nextera technology could enable J&J to intercept RA before it starts

Johnson & Johnson's option deal with Nextera A/S could add another tool to the pharma's growing arsenal of T cell-based technologies for intercepting immunological diseases before they start.

On Sept. 21, Nextera granted J&J's Janssen Biotech Inc. unit an option to exclusively license the biotech's Phagemer technology for rheumatoid arthritis. Janssen initially will fund a research program. Additional details of the deal, including what triggers the option, were not disclosed.

Phagemer uses phage display of recombinant major histocompatibility complex (MHC) class II molecules to screen for T cell targets of interest. MHC class II molecules on antigen-presenting cells

Read the full 975 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers